NEWS-PrimeLink BioTherapeutics_ADC Biotechnology

Home page

2026 CHIC | PrimeLink Bio to Share PLB-002 Clinical Progress and Latest Dual-Payload ADC Platform Advances

2026 CHIC | PrimeLink Bio to Share PLB-002 Clinical Progress and Latest Dual-Payload ADC Platform Advances

23 Mar,2026

PrimeLink Bio Achieves ADC Pipeline Breakthrough: First Patient Dosed in Phase I Trial of PLB-002

PrimeLink Bio Achieves ADC Pipeline Breakthrough: First Patient Dosed in Phase I Trial of PLB-002

09 Feb,2026

PrimeLink Bio’s PLB-002 Wins NMPA IND Approval, Marking China-US Dual Filing

PrimeLink Bio’s PLB-002 Wins NMPA IND Approval, Marking China-US Dual Filing

20 Nov,2025

Flexible, Modular Tech Platform Overcomes Conventional ADC Toxicity and Resistance Limits

Flexible, Modular Tech Platform Overcomes Conventional ADC Toxicity and Resistance Limits

02 Jan,2025

FDA Greenlights PrimeLink Bio’s Clinical Trial of PLB-002

FDA Greenlights PrimeLink Bio’s Clinical Trial of PLB-002

09 Oct,2025

Dual-Payload ADCs: A New Chapter in Cancer Therapy

Dual-Payload ADCs: A New Chapter in Cancer Therapy

10 Mar,2025

< 1 2 >

免费热线

Tel:

0086 512-62652000

免费热线

E-mail:

hr@primelinkbio.com

Add:

Building 4, Suhua Science Park , No.208 Tongyuan Road, Suzhou Industrial Park

Follow Us

©2022 PrimeLink BioTherapeutics Powered by：CEglobal